Summary
- CVS accountants went Good Will Hunting and found that the company overpaid for Omnicare.
- 2019 estimates also came in below Wall Street estimates.
- The challenge now is to show that Aetna was a good acquisition.
- We lowered our fair value of the stock but it is still above where the company trades today.
- This idea was discussed in more depth with members of my private investing community, The Wheel of FORTUNE. Start your free trial today ยป
CVS Health Corporation (CVS) has been one we have followed for some time. We have traded in and out of it when it was a standalone corporation. We essentially saw it as a fallen growth angel struck by fears of Amazon (AMZN). However, the acquisition of Aetna dramatically changed the complexity and risk-reward of the stock.
Specifically, we believed that Wall Street was too optimistic on 2019 estimates in the face of reimbursement pressures on healthcare spending. This was validated when CVS dramatically lowered 2019 estimates last week. Last quarter results also saw CVS take a big hit on its Omnicare arm which provides services to long-term assisted living and skilled nursing facilities. The combination tanked the stock and it is now at a 5 year low.
Data by
